Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma

Article type: Research Article

Authors: Zhang, Nan^{a; 1} | Cong, Xiaoqiang^{b; 1} | Zhou, Dan^c | Guo, Liang^d | Yuan, Congwang^e | Xu, Dahai^{a; 1; *} | Su, Chang^{f; *}

Affiliations: [a] Department of Emergency, The First Hospital of Jilin University, Changchun, Jilin 130021, China | [b] Department of Cardiology, The First Hospital of Jilin University, Changchun, Jilin 130021, China | [c] Department of Pediatrics, The Second Hospital of Jilin University, Changchun, Jilin 130041, China | [d] Department of Pathology, The First Hospital of Jilin University, Changchun, Jilin 130021, China | [e] Department of Pain, Yancheng First People’s Hospital, Yancheng, Jiangsu 224000, China | [f] Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China

Correspondence: [*] Corresponding authors: Dahai Xu, Department of Emergency, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. Tel.: +86 431 88782203; Fax: +86 431 8565 4528; E-mail: yangzhouxux@sina.com. Chang Su, Department of Thyroid Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. Tel.: +86 431 88782203; Fax: +86 431 85654528; E-mail: keaisuchang@sina.com.

Note: [1] These authors contributed equally to this work.

Abstract: BACKGROUND: The significance of serum dipeptidyl peptidase-IV (DPP-IV) in papillary thyroid carcinoma (PTC) has not been elucidated. OBJECTIVE: This study aimed to assess the role of serum DPP-IV in the carcinogenesis and prognosis of PTC. METHODS: The serum DPP-IV concentration was measured in 171 male patients with PTC, 81 male patients with a benign thyroid nodule (BTN), and 52 male healthy controls (HCs). Multivariate logistic regression and Cox regression analyses were performed to evaluate the correlations between variables. Receiver operating characteristic (ROC) curves were used to calculate the diagnosis accuracy. RESULTS: The ROC curve indicated a good performance of DPP-IV for discriminating PTC from BTN, with an area under the curve (AUC) of 0.881 (95% CI, 0.840–0.922). Serum DPP-IV demonstrated a modest performance in predicting nonstructurally persistent disease/recurrent disease (NSPRD) survival, with an AUC of 0.778 (95% CI, 0.635–0.922). A serum DPP-IV level ⩾ 250 nkat/L (HR, 6.529; 95% CI, 2.090–20.398; P= 0.001) and an advanced tumor, lymph node, metastasis (TNM) stage (HR, 4.677; 95% CI, 1.498–14.605; P= 0.008) were found to be independent factors for predicting SPRD. PTC patients with a DPP-IV level ⩾ 250 nkat/L had a worse outcome than those with a DPP-IV level < 250 nkat/L (P< 0.001). CONCLUSIONS: Serum DPP-IV may be a predictive biomarker for PTC diagnosis and prognosis in Chinese male patients.

Keywords: Dipeptidyl peptidase-IV, CD26, papillary thyroid carcinoma, structurally persistent, recurrent disease

DOI: 10.3233/CBM-170908

Journal: Cancer Biomarkers, vol. 24, no. 1, pp. 7-17, 2019